Paraoxonase 1 Activity in Patients with Chronic Obstructive Pulmonary Disease
Authors:
- Marija Grdić RajkovićMRMarija Grdić Rajković
- Lara Milevoj KopčinovićLKLara Milevoj Kopčinović
- Dolores PancirovDPDolores Pancirov
- Ivana ČepelakIČIvana Čepelak
- Tihana Žanić GrubišićTGTihana Žanić Grubišić
- 15 May 2014
- journal article
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 11 (5) , 539-545
Abstract
Paraoxonase 1 (PON1) is an antioxidative enzyme manly associated with high density lipoproteins (HDL) in the peripheral blood. The aim of this study was to determine the PON1 paraoxonase and arylesterase activities in patients with chronic obstructive pulmonary disease (COPD). We also aimed to determine the concentration of reduced thiol groups as a marker of protein oxidation. The study included 105 patients with stable COPD and 44 healthy controls. PON1 activities and thiols concentration were assayed in sera by spectrophotometry. PON1 basal (POX) and salt-stimulated paraoxonase activity (POX1) as well as arylesterase activity (ARE) were significantly reduced in COPD patients. In addition, concentration of reduced thiol groups was significantly decreased in COPD group. PON1 activities were similar in patients with different disease severity (GOLD stages). However, a significant reduction in POX, POX1 and ARE was observed already in GOLD II stage when compared to controls. POX and POX1 showed modest while ARE yielded very good power for discrimination between healthy subjects and COPD patients. Univariate and multivariate logistic regression analysis indicated that ARE is a good COPD predictor. Reduction of PON1 activity observed in COPD patients could be partly caused by oxidative environment. Lower concentrations of reduced thiol groups in COPD patients suggest that a decrease in PON1 activity could reflect oxidative changes of enzyme free cysteine residues. Furthermore, decreased PON1 arylesterase activity might indicate a down-regulation of PON1 concentration. Our results suggest that ARE could be considered as potential biomarker for COPD diagnosis.Keywords
This publication has 44 references indexed in Scilit:
- Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPDClinical Biochemistry, 2012
- Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbationRespiratory Medicine, 2011
- Chronic Obstructive Pulmonary Disease and Paraoxonase-1 192 and 55 Gene PolymorphismsBiotechnology & Biotechnological Equipment, 2010
- Oxidative Stress in Smokers and Non-smokersInhalation Toxicology, 2007
- The paraoxonase gene family and atherosclerosisFree Radical Biology and Medicine, 2005
- Pharmacogenetics of paraoxonases: a brief reviewNaunyn-Schmiedeberg's Archives of Pharmacology, 2004
- Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3Biochemical Pharmacology, 2003
- Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. implications for its physiological roleChemico-Biological Interactions, 2001
- Calcium-dependent Human Serum Homocysteine Thiolactone HydrolaseJournal of Biological Chemistry, 2000
- The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarinNature Genetics, 1996